Do analysts rate NCEL or UPXI?

Upexi has a consensus target price of $8.33, indicating a potential upside of 935.20%. Given Upexi's stronger consensus rating and higher probable upside, analysts clearly believe Upexi is more favorable than NLS Pharmaceutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Upexi 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has better earnings and valuation, NCEL or UPXI?

NLS Pharmaceutics has higher earnings, but lower revenue than Upexi. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Upexi $15.81M 3.58 -$13.68M -$0.62 N/A

Do analysts rate BYSI or NCEL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, BYSI or NCEL?

BeyondSpring has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeyondSpring $1.75M 37.83 -$1.01M -$0.14 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is BYSI or NCEL more profitable?

Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% NLS Pharmaceutics N/A N/A N/A

Do analysts prefer NCEL or CING?

Cingulate has a consensus price target of $27.33, suggesting a potential upside of 467.79%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than NLS Pharmaceutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better earnings and valuation, NCEL or CING?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Cingulate N/A N/A -$22.45M -$4.23 N/A

Is NCEL or CING more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Cingulate N/A -365.15% -158.55%

Do analysts recommend NCEL or BHST?

BioHarvest Sciences has a consensus target price of $10.00, indicating a potential upside of 207.60%. Given BioHarvest Sciences' stronger consensus rating and higher probable upside, analysts plainly believe BioHarvest Sciences is more favorable than NLS Pharmaceutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioHarvest Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, NCEL or BHST?

NLS Pharmaceutics has higher earnings, but lower revenue than BioHarvest Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A BioHarvest Sciences $35.16M 1.81 -$11.14M -$0.59 N/A

Do analysts recommend ACRV or NCEL?

Acrivon Therapeutics currently has a consensus price target of $11.67, suggesting a potential upside of 604.93%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Acrivon Therapeutics is more favorable than NLS Pharmaceutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, ACRV or NCEL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is ACRV or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -64.43% -57.08% NLS Pharmaceutics N/A N/A N/A

NLS Pharmaceutics (NCEL) Competitors

$3.55 +0.06 (+1.72%)

As of 09:31 AM Eastern

Compare

NCEL vs. UPXI, BYSI, CING, BHST, and ACRV

Should you buy NLS Pharmaceutics stock or one of its competitors? MarketBeat compares NLS Pharmaceutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NLS Pharmaceutics include Upexi (UPXI), BeyondSpring (BYSI), Cingulate (CING), BioHarvest Sciences (BHST), and Acrivon Therapeutics (ACRV). These companies are all part of the "pharmaceutical products" industry.

How does NLS Pharmaceutics compare to Upexi?

NLS Pharmaceutics (NASDAQ:NCEL) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

NLS Pharmaceutics has a net margin of 0.00% compared to Upexi's net margin of -874.00%. NLS Pharmaceutics' return on equity of 0.00% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Upexi	-874.00%	-66.70%	-19.56%

NLS Pharmaceutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Upexi has a beta of -0.35, indicating that its stock price is 135% less volatile than the broader market.

NLS Pharmaceutics has higher earnings, but lower revenue than Upexi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Upexi	$15.81M	3.58	-$13.68M	-$0.62	N/A

In the previous week, Upexi had 2 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 2 mentions for Upexi and 0 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.00 equaled Upexi'saverage media sentiment score.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
Upexi	Neutral

5.7% of Upexi shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 9.0% of Upexi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Upexi has a consensus target price of $8.33, indicating a potential upside of 935.20%. Given Upexi's stronger consensus rating and higher probable upside, analysts clearly believe Upexi is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Upexi beats NLS Pharmaceutics on 7 of the 13 factors compared between the two stocks.

How does NLS Pharmaceutics compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BeyondSpring has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
NLS Pharmaceutics	N/A	N/A	N/A

40.3% of BeyondSpring shares are held by institutional investors. 29.3% of BeyondSpring shares are held by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BeyondSpring's average media sentiment score of 0.00 equaled NLS Pharmaceutics'average media sentiment score.

Company	Overall Sentiment
BeyondSpring	Neutral
NLS Pharmaceutics	Neutral

BeyondSpring has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	37.83	-$1.01M	-$0.14	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

Summary

BeyondSpring beats NLS Pharmaceutics on 4 of the 6 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Cingulate?

NLS Pharmaceutics (NASDAQ:NCEL) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

41.3% of Cingulate shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 5.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NLS Pharmaceutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.85, suggesting that its share price is 185% less volatile than the broader market.

NLS Pharmaceutics' return on equity of 0.00% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Cingulate	N/A	-365.15%	-158.55%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

Cingulate has a consensus price target of $27.33, suggesting a potential upside of 467.79%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Cingulate had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for Cingulate and 0 mentions for NLS Pharmaceutics. Cingulate's average media sentiment score of 0.84 beat NLS Pharmaceutics' score of 0.00 indicating that Cingulate is being referred to more favorably in the news media.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
Cingulate	Positive

Summary

Cingulate beats NLS Pharmaceutics on 6 of the 11 factors compared between the two stocks.

How does NLS Pharmaceutics compare to BioHarvest Sciences?

NLS Pharmaceutics (NASDAQ:NCEL) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

NLS Pharmaceutics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. NLS Pharmaceutics' return on equity of 0.00% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

BioHarvest Sciences has a consensus target price of $10.00, indicating a potential upside of 207.60%. Given BioHarvest Sciences' stronger consensus rating and higher probable upside, analysts plainly believe BioHarvest Sciences is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, BioHarvest Sciences had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for BioHarvest Sciences and 0 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.00 equaled BioHarvest Sciences'average media sentiment score.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
BioHarvest Sciences	Neutral

NLS Pharmaceutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

NLS Pharmaceutics has higher earnings, but lower revenue than BioHarvest Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
BioHarvest Sciences	$35.16M	1.81	-$11.14M	-$0.59	N/A

Summary

NLS Pharmaceutics and BioHarvest Sciences tied by winning 5 of the 10 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Acrivon Therapeutics currently has a consensus price target of $11.67, suggesting a potential upside of 604.93%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Acrivon Therapeutics is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

71.6% of Acrivon Therapeutics shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NLS Pharmaceutics' return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
NLS Pharmaceutics	N/A	N/A	N/A

Acrivon Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

In the previous week, Acrivon Therapeutics had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for Acrivon Therapeutics and 0 mentions for NLS Pharmaceutics. Acrivon Therapeutics' average media sentiment score of 0.00 equaled NLS Pharmaceutics'average media sentiment score.

Company	Overall Sentiment
Acrivon Therapeutics	Neutral
NLS Pharmaceutics	Neutral

Summary

Acrivon Therapeutics beats NLS Pharmaceutics on 6 of the 10 factors compared between the two stocks.

Get NLS Pharmaceutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCEL vs. The Competition

Export

Metric	NLS Pharmaceutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.98M	$3.01B	$6.58B	$12.14B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	N/A	18.64	24.81	24.06
Price / Sales	N/A	482.11	552.47	123.81
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	2.23	4.18	10.77	6.51
Net Income	-$8.30M	$64.45M	$3.56B	$337.03M
7 Day Performance	12.70%	2.73%	1.97%	0.10%
1 Month Performance	12.34%	2.33%	1.45%	1.07%
1 Year Performance	-84.36%	25.36%	31.07%	28.66%

NLS Pharmaceutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCEL NLS Pharmaceutics	0.5928 of 5 stars	$3.55 +1.7%	N/A	-84.8%	$18.98M	N/A	N/A	6
UPXI Upexi	1.9942 of 5 stars	$0.97 +1.4%	$8.33 +763.6%	-91.7%	$68.08M	$15.81M	N/A	130	Gap Down
BYSI BeyondSpring	0.0438 of 5 stars	$1.63 +1.9%	N/A	-41.2%	$67.40M	N/A	N/A	80	Positive News Gap Down
CING Cingulate	3.2925 of 5 stars	$5.01 +5.7%	$27.33 +445.4%	+19.6%	$67.28M	N/A	N/A	20	Gap Up
BHST BioHarvest Sciences	2.3697 of 5 stars	$3.36 +1.4%	$10.00 +198.0%	-54.6%	$65.85M	$34.51M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCEL) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. UPXI, BYSI, CING, BHST, and ACRV

How does NLS Pharmaceutics compare to Upexi?

Summary

How does NLS Pharmaceutics compare to BeyondSpring?

Summary

How does NLS Pharmaceutics compare to Cingulate?

Summary

How does NLS Pharmaceutics compare to BioHarvest Sciences?

Summary

How does NLS Pharmaceutics compare to Acrivon Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. UPXI, BYSI, CING, BHST, and ACRV

How does NLS Pharmaceutics compare to Upexi?

Is NCEL or UPXI more profitable?

Which has more risk and volatility, NCEL or UPXI?

Which has better earnings and valuation, NCEL or UPXI?

Does the media prefer NCEL or UPXI?

Do institutionals & insiders believe in NCEL or UPXI?

Do analysts rate NCEL or UPXI?

Summary

How does NLS Pharmaceutics compare to BeyondSpring?

Do analysts rate BYSI or NCEL?

Which has more risk and volatility, BYSI or NCEL?

Is BYSI or NCEL more profitable?

Do insiders & institutionals hold more shares of BYSI or NCEL?

Does the media favor BYSI or NCEL?

Which has stronger earnings & valuation, BYSI or NCEL?

Summary

How does NLS Pharmaceutics compare to Cingulate?

Do insiders and institutionals hold more shares of NCEL or CING?

Which has more risk and volatility, NCEL or CING?

Is NCEL or CING more profitable?

Which has better earnings and valuation, NCEL or CING?

Do analysts prefer NCEL or CING?

Does the media prefer NCEL or CING?

Summary

How does NLS Pharmaceutics compare to BioHarvest Sciences?

Is NCEL or BHST more profitable?

Do analysts recommend NCEL or BHST?

Does the media prefer NCEL or BHST?

Which has more volatility & risk, NCEL or BHST?

Which has better valuation & earnings, NCEL or BHST?

Summary

How does NLS Pharmaceutics compare to Acrivon Therapeutics?

Do analysts recommend ACRV or NCEL?

Which has stronger valuation and earnings, ACRV or NCEL?

Do institutionals and insiders hold more shares of ACRV or NCEL?

Is ACRV or NCEL more profitable?

Which has more volatility and risk, ACRV or NCEL?

Does the media favor ACRV or NCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools